Evidence map›Paper›PMID 34070677›Full record

ArticleCancers2021

Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).

Philip Zeuschner, Sebastian Hölters, Michael Stöckle, Barbara Seliger, Anja Mueller, Hagen S Bachmann, Viktor Grünwald, Daniel C Christoph, Arnulf Stenzl, Marc-Oliver Grimm and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 1 country.

Philip ZeuschnerDepartment of Urology and Pediatric Urology, Saarland University, Kirrberger Street, 66421 Homburg/Saar, Germany.ORCID 0000-0001-8898-6588
Sebastian HöltersDepartment of Urology and Pediatric Urology, Saarland University, Kirrberger Street, 66421 Homburg/Saar, Germany.
Michael StöckleDepartment of Urology and Pediatric Urology, Saarland University, Kirrberger Street, 66421 Homburg/Saar, Germany.
Barbara SeligerInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, Universitätsplatz 10, 06108 Halle (Saale), Germany.ORCID 0000-0002-5544-4958
Anja MuellerInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, Universitätsplatz 10, 06108 Halle (Saale), Germany.
Hagen S BachmannCenter for Biomedical Education and Research (ZBAF), Faculty of Health, Institute of Pharmacology and Toxicology, School of Medicine, Witten/Herdecke University, Stockumer Straße 10, 58453 Witten, Germany.
Viktor GrünwaldDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, University Hospital, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
Daniel C ChristophDepartment of Medical Oncology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany.
Arnulf StenzlDepartment of Urology, University Hospital Tuebingen, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany.ORCID 0000-0003-4207-9928
Marc-Oliver GrimmDepartment of Urology, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.ORCID 0000-0003-3084-8654
Fabian BrüningDepartment of Urology and Pediatric Urology, University Hospital Giessen and Marburg GmbH, Philipps-University Marburg, Baldingerstrasse, 35033 Marburg, Germany.
Peter J GoebellAmbulatory Uro-Oncological Therapy Unit Erlangen (AURONTE), Department of Urology and Clinic for Haematology and Internistic Oncology, University Hospital Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.ORCID 0000-0003-0176-4478
Marinela AugustinDepartment of Hematology and Oncology, Paracelsus Medical University, Prof.-Ernst-Nathan-Strasse 1, 90419 Nürnberg, Germany.ORCID 0000-0003-0494-0422
Frederik RoosDepartment of Urology and Paediatric Urology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Johanna HardeMedical Department, iOMEDICO, Ellen-Gottlieb-Strasse 19, 70106 Freiburg im Breisgau, Germany.
Iris Benz-RüdMedical Department, iOMEDICO, Ellen-Gottlieb-Strasse 19, 70106 Freiburg im Breisgau, Germany.
Michael StaehlerInterdisciplinary Center of Renal Tumors, Department of Urology, Ludwig-Maximilians-University of Munich, Marchioninistrasse 15, 81377 Munich, Germany.ORCID 0000-0002-4574-6522
Kerstin JunkerDepartment of Urology and Pediatric Urology, Saarland University, Kirrberger Street, 66421 Homburg/Saar, Germany.ORCID 0000-0002-0873-8128
Saarland University · DEIomedico (Germany) · DEMartin Luther University Halle-Wittenberg · DEEssen University Hospital · DEGoethe University Frankfurt · DEJena University Hospital · DELudwig-Maximilians-Universität München · DEMedizinische Hochschule Hannover · DEParacelsus Medizinische Privatuniversität · DEUniversitätsklinikum Erlangen · DEUniversitätsklinikum Gießen und Marburg · DEWitten/Herdecke University · DE

Funding

iOMEDICO none
6 · The paper itself

Abstract

There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, potential biomarkers were assessed employing proteomics, ELISA, and polymorphism analyses. Lower levels of angiogenesis-related protein thrombospondin-2 (TSP-2) at baseline (≤665 parts per billion, ppb) identified therapy responders with longer median progression-free survival (PFS; ≤665 ppb at baseline: 6.9 months vs. 1.8,

Indexed as

biomarkereverolimusmetastatic renal cell carcinomaphase IVsecond-line

Identifiers

PMID34070677
PMCPMC8199288
OpenAlexW3164935163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.